TY  - RPRT
TI  - Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.
AU  - Tomas Olsson
AU  - Xavier Montalban
AU  - Reinhard Hohlfeld
AU  - Carlo Pozzilli
AU  - Mark S Freedman
AU  - Till Sprenger
AU  - Robert J Fox
AU  - Eva Kubala Havrdova
AU  - Fred Lublin
AU  - Nandini Raghavan
AU  - Janice Wong
AU  - Andrea Vaclavkova
AU  - Magdalena Pirozek-Lawniczek
AU  - Amita Singh
AU  - Michel Burcklen
AU  - Ludwig Kappos
PY  - 2026
DO  - 10.1016/j.msard.2026.107403
UR  - https://pubmed.ncbi.nlm.nih.gov/42561748/
ID  - 42561748
ER  -